
Dysmenorrhea Market Report and Forecast 2024-2032
Description
Dysmenorrhea Market Report and Forecast 2024-2032
Dysmenorrhea Market Report and Forecast 2024-2032
Dysmenorrhea Market Outlook
The dysmenorrhea market size is anticipated to grow at a CAGR of 5.7 % during the forecast period of 2024-2032, driven by the rising incidence of PCOS and other hormonal issues across the major markets.
Dysmenorrhea: Introduction
Dysmenorrhea refers to painful menstrual cramps in women, often accompanied by lower abdomen discomfort. It's divided into primary, linked to menstruation without underlying disease, and secondary, stemming from reproductive system disorders. Symptoms include sharp, throbbing, or dull pain, and may involve nausea, fatigue, and headache. Treatment typically involves pain relievers, hormonal contraceptives to lessen severity, and lifestyle changes like exercise and diet. In severe cases, especially in secondary dysmenorrhea, medical evaluation is essential for appropriate treatment.
Key Trends in the Dysmenorrhea Market
There is a growing global movement towards better awareness and education about menstrual health. This trend is leading to more women seeking treatment for dysmenorrhea and a greater understanding of the condition among healthcare providers.
While medication remains a primary treatment for dysmenorrhea, there is an increasing interest in non-pharmacological approaches. These include lifestyle changes, dietary adjustments, physical therapy, yoga, and acupuncture. Such treatments are gaining popularity due to their minimal side effects and holistic benefits.
The use of digital health tools, such as menstrual tracking apps and telehealth services, is on the rise. These tools help women better understand their menstrual cycle, track symptoms, and seek timely medical advice.
There is a growing trend towards personalized medicine in treating dysmenorrhea. This approach involves tailoring treatment plans to individual patient needs, considering factors like the severity of symptoms, underlying health conditions, and personal preferences.
Innovation in pain management, including new formulations of NSAIDs and other pain relief medications, is a significant trend. These advancements aim to provide more effective and longer-lasting relief with fewer side effects.
Integrative medicine, which combines conventional medical treatments with alternative therapies, is becoming more popular in managing dysmenorrhea. This approach is focused on treating the whole person, not just the symptoms.
The broader women’s health movement, advocating for better healthcare services and research focused on women’s health issues, is positively impacting the dysmenorrhea market. It's leading to more research, better treatment options, and a reduction in the stigma associated with menstrual health.
Dysmenorrhea Market Segmentation
Market Breakup by Treatment Type
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Hormonal Therapy
- Primary Dysmenorrhea
- Secondary Dysmenorrhea
- Hospitals
- Homecare
- Specialty Clinics
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
In the United States, the market is driven by a high awareness of menstrual health and the availability of various treatment options. The U.S. market sees a significant emphasis on over the counter (OTC) pain relievers and prescription medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal contraceptives. There's also a growing interest in alternative therapies like acupuncture and dietary supplements.
Europe's market is characterized by a strong healthcare system that supports women's health. European countries generally have higher government involvement in healthcare, which influences the availability and affordability of treatments. Prescription medications are commonly used, and there's an increasing focus on holistic and lifestyle approaches, including diet modifications and physical therapy.
In Japan, cultural attitudes towards menstrual health influence the market. There's a notable preference for discretion and privacy in treatment. The Japanese market includes a mix of Western medicines and traditional Japanese treatments, like herbal remedies. The use of technology in symptom tracking and telemedicine for consultation is also gaining traction.
Dysmenorrhea Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- Bayer AG
- Abbott Laboratories
- F. Hoffmann-La Roche Ltd
- Sanofi
- Pfizer Inc.
- GlaxoSmithKline PLC
- Focus Consumer Healthcare
- Johnson & Johnson
- Alvogen
- Amgen Inc.
- Boehringer Ingelheim International GmbH.
- Ipsen Pharm
- Spectrum Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
180 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Dysmenorrhea Overview
- 3.1 Guidelines and Stages
- 3.2 Pathophysiology
- 3.3 Screening and Diagnosis
- 3.4 Treatment Pathway
- 4 Patient Profile
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Dysmenorrhea Epidemiology Analysis – 7MM
- 5.1 7MM Epidemiology Scenario Overview (2017-2032)
- 5.2 United States Dysmenorrhea Epidemiology Forecast (2017-2032)
- 5.3 EU-4 and United Kingdom Dysmenorrhea Epidemiology Forecast (2017-2032)
- 5.3.1 Germany Dysmenorrhea Epidemiology Forecast (2017-2032)
- 5.3.2 France Dysmenorrhea Epidemiology Forecast (2017-2032)
- 5.3.3 Italy Dysmenorrhea Epidemiology Forecast (2017-2032)
- 5.3.4 Spain Dysmenorrhea Epidemiology Forecast (2017-2032)
- 5.3.5 United Kingdom Dysmenorrhea Epidemiology Forecast (2017-2032)
- 5.4 Japan Dysmenorrhea Epidemiology Forecast (2017-2032)
- 6 Dysmenorrhea Market Overview – 7MM
- 6.1 Dysmenorrhea Market Historical Value (2017-2023)
- 6.2 Dysmenorrhea Market Forecast Value (2024-2032)
- 7 Dysmenorrhea Market Landscape – 7MM
- 7.1 Dysmenorrhea: Developers Landscape
- 7.1.1 Analysis by Year of Establishment
- 7.1.2 Analysis by Company Size
- 7.1.3 Analysis by Region
- 7.2 Dysmenorrhea Product Landscape
- 7.2.1 Analysis by Treatment Type
- 7.2.2 Analysis by Route of Administration
- 7.2.3 Analysis by Treatment Type
- 8 Dysmenorrhea Challenges and Unmet Needs
- 8.1 Treatment Pathway Challenges
- 8.2 Compliance and Drop-Out Analysis
- 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Dysmenorrhea Market Dynamics
- 10.1 Market Drivers and Constraints
- 10.2 SWOT Analysis
- 10.3 Porter’s Five Forces Model
- 10.4 Key Demand Indicators
- 10.5 Key Price Indicators
- 10.6 Industry Events, Initiatives, and Trends
- 10.7 Value Chain Analysis
- 11 Dysmenorrhea Market Segmentation – 7MM
- 11.1 Dysmenorrhea Market by Treatment Type
- 11.1.1 Market Overview
- 11.1.2 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- 11.1.3 Hormonal Therapy
- 11.2 Dysmenorrhea Market by Disease Type
- 11.2.1 Market Overview
- 11.2.2 Primary Dysmenorrhea
- 11.2.3 Secondary Dysmenorrhea
- 11.3 Dysmenorrhea Market by End User
- 11.3.1 Market Overview
- 11.3.2 Hospitals
- 11.3.3 Homecare
- 11.3.4 Specialty Clinics
- 11.3.5 Others
- 11.4 Dysmenorrhea Market by Region
- 11.4.1 Market Overview
- 11.4.2 United States
- 11.4.3 EU-4 and the United Kingdom
- 11.4.3.1 Germany
- 11.4.3.2 France
- 11.4.3.3 Italy
- 11.4.3.4 Spain
- 11.4.3.5 United Kingdom
- 11.4.4 Japan
- 12 United States Dysmenorrhea Market
- 12.1 Dysmenorrhea Market Historical Value (2017-2023)
- 12.2 Dysmenorrhea Market Forecast Value (2024-2032)
- 12.3 Dysmenorrhea Market by Disease Type
- 12.4 Dysmenorrhea Market by Treatment Type
- 13 EU-4 and United Kingdom Dysmenorrhea Market
- 13.1 Dysmenorrhea Market Historical Value (2017-2023)
- 13.2 Dysmenorrhea Market Forecast Value (2024-2032)
- 13.3 Germany Dysmenorrhea Market Overview
- 13.3.1 Dysmenorrhea Market by Disease Type
- 13.3.2 Dysmenorrhea Market by Treatment Type
- 13.4 France Dysmenorrhea Market Overview
- 13.4.1 Dysmenorrhea Market by Disease Type
- 13.4.2 Dysmenorrhea Market by Treatment Type
- 13.5 Italy Dysmenorrhea Market Overview
- 13.5.1 Dysmenorrhea Market by Disease Type
- 13.5.2 Dysmenorrhea Market by Treatment Type
- 13.6 Spain Dysmenorrhea Market Overview
- 13.6.1 Dysmenorrhea Market by Disease Type
- 13.6.2 Dysmenorrhea Market by Treatment Type
- 13.7 United Kingdom Dysmenorrhea Market Overview
- 13.7.1 Dysmenorrhea Market by Disease Type
- 13.7.2 Dysmenorrhea Market by Treatment Type
- 14 Japan Dysmenorrhea Market
- 14.1 Dysmenorrhea Market Historical Value (2017-2023)
- 14.2 Dysmenorrhea Market Forecast Value (2024-2032)
- 14.3 Dysmenorrhea Market by Disease Type
- 14.4 Dysmenorrhea Market by Treatment Type
- 15 Regulatory Framework
- 15.1 Regulatory Overview
- 15.1.1 US FDA
- 15.1.2 EU EMA
- 15.1.3 JAPAN PMDA
- 16 Patent Analysis
- 16.1 Analysis by Type of Patent
- 16.2 Analysis by Publication year
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Patent Age
- 16.5 Analysis by CPC Analysis
- 16.6 Analysis by Patent Valuation
- 16.7 Analysis by Key Players
- 17 Grants Analysis
- 17.1 Analysis by year
- 17.2 Analysis by Amount Awarded
- 17.3 Analysis by Issuing Authority
- 17.4 Analysis by Grant Application
- 17.5 Analysis by Funding Institute
- 17.6 Analysis by NIH Departments
- 17.7 Analysis by Recipient Organization
- 18 Clinical Trials Analysis
- 18.1 Analysis by Trial Registration Year
- 18.2 Analysis by Trial Status
- 18.3 Analysis by Trial Phase
- 18.4 Analysis by Therapeutic Area
- 18.5 Analysis by Geography
- 19 Funding and Investment Analysis
- 19.1 Analysis by Funding Instances
- 19.2 Analysis by Type of Funding
- 19.3 Analysis by Funding Amount
- 19.4 Analysis by Leading Players
- 19.5 Analysis by Leading Investors
- 19.6 Analysis by Geography
- 20 Partnerships and Collaborations Analysis
- 20.1 Analysis by Partnership Instances
- 20.2 Analysis by Type of Partnership
- 20.3 Analysis by Leading Players
- 20.4 Analysis by Geography
- 21 Supplier Landscape
- 21.1 Novartis AG
- 21.1.1 Financial Analysis
- 21.1.2 Product Portfolio
- 21.1.3 Demographic Reach and Achievements
- 21.1.4 Mergers and Acquisitions
- 21.1.5 Certifications
- 21.2 Bayer AG
- 21.2.1 Financial Analysis
- 21.2.2 Product Portfolio
- 21.2.3 Demographic Reach and Achievements
- 21.2.4 Mergers and Acquisitions
- 21.2.5 Certifications
- 21.3 Abbott Laboratories
- 21.3.1 Financial Analysis
- 21.3.2 Product Portfolio
- 21.3.3 Demographic Reach and Achievements
- 21.3.4 Mergers and Acquisitions
- 21.3.5 Certifications
- 21.4 F. Hoffmann-La Roche Ltd
- 21.4.1 Financial Analysis
- 21.4.2 Product Portfolio
- 21.4.3 Demographic Reach and Achievements
- 21.4.4 Mergers and Acquisitions
- 21.4.5 Certifications
- 21.5 Sanofi
- 21.5.1 Financial Analysis
- 21.5.2 Product Portfolio
- 21.5.3 Demographic Reach and Achievements
- 21.5.4 Mergers and Acquisitions
- 21.5.5 Certifications
- 21.6 Pfizer Inc.
- 21.6.1 Financial Analysis
- 21.6.2 Product Portfolio
- 21.6.3 Demographic Reach and Achievements
- 21.6.4 Mergers and Acquisitions
- 21.6.5 Certifications
- 21.7 GlaxoSmithKline PLC
- 21.7.1 Financial Analysis
- 21.7.2 Product Portfolio
- 21.7.3 Demographic Reach and Achievements
- 21.7.4 Mergers and Acquisitions
- 21.7.5 Certifications
- 21.8 Focus Consumer Healthcare
- 21.8.1 Financial Analysis
- 21.8.2 Product Portfolio
- 21.8.3 Demographic Reach and Achievements
- 21.8.4 Mergers and Acquisitions
- 21.8.5 Certifications
- 21.9 Johnson & Johnson
- 21.9.1 Financial Analysis
- 21.9.2 Product Portfolio
- 21.9.3 Demographic Reach and Achievements
- 21.9.4 Mergers and Acquisitions
- 21.9.5 Certifications
- 21.10 Alvogen
- 21.10.1 Financial Analysis
- 21.10.2 Product Portfolio
- 21.10.3 Demographic Reach and Achievements
- 21.10.4 Mergers and Acquisitions
- 21.10.5 Certifications
- 21.11 Amgen Inc.
- 21.11.1 Financial Analysis
- 21.11.2 Product Portfolio
- 21.11.3 Demographic Reach and Achievements
- 21.11.4 Mergers and Acquisitions
- 21.11.5 Certifications
- 21.12 Boehringer Ingelheim International GmbH.
- 21.12.1 Financial Analysis
- 21.12.2 Product Portfolio
- 21.12.3 Demographic Reach and Achievements
- 21.12.4 Mergers and Acquisitions
- 21.12.5 Certifications
- 21.13 Ipsen Pharm
- 21.13.1 Financial Analysis
- 21.13.2 Product Portfolio
- 21.13.3 Demographic Reach and Achievements
- 21.13.4 Mergers and Acquisitions
- 21.13.5 Certifications
- 21.14 Spectrum Pharmaceuticals, Inc.
- 21.14.1 Financial Analysis
- 21.14.2 Product Portfolio
- 21.14.3 Demographic Reach and Achievements
- 21.14.4 Mergers and Acquisitions
- 21.14.5 Certifications
- 21.15 Takeda Pharmaceutical Company Limited
- 21.15.1 Financial Analysis
- 21.15.2 Product Portfolio
- 21.15.3 Demographic Reach and Achievements
- 21.15.4 Mergers and Acquisitions
- 21.15.5 Certifications
- 22 Dysmenorrhea Market- Distribution Model (Additional Insight)
- 22.1 Overview
- 22.2 Potential Distributors
- 22.3 Key Parameters for Distribution Partner Assessment
- 23 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 24 Company Competitiveness Analysis (Additional Insight)
- 24.1 Very Small Companies
- 24.2 Small Companies
- 24.3 Mid-Sized Companies
- 24.4 Large Companies
- 24.5 Very Large Companies
- 25 Payment Methods (Additional Insight)
- 25.1 Government Funded
- 25.2 Private Insurance
- 25.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.